GLYCOBIA, INC.

Company Information

Company Name
GLYCOBIA, INC.
Address
33 Thornwood Drive
ITHACA, NY, -
Phone
n/a
URL
n/a
DUNS
824602135
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,662,013.00
8
SBIR Phase II
$1,608,039.00
1

Award List

  1. Therapeutic antibody fragments from glycoengineered Escherichia coli

    Amount: $391,734.00

    DESCRIPTION (provided by applicant): Omalizumab (XolairTM) is a recombinant monoclonal anti-IgE antibody used in the fight against severe allergic asthma that generates 500 million per year. However, ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. Conjugation of polysialic acid to biologics in glycoengineered Escherichia coli

    Amount: $199,020.00

    DESCRIPTION (provided by applicant): Biotherapeutics currently constitute a 70 billion market, but their clinical efficacy is often compromised by limitations arising from proteolytic degradation, up ...

    SBIR Phase I 2010 Department of Health and Human Services
  3. Humanizing N-linked glycosylation in Escherichia coli

    Amount: $115,988.00

    DESCRIPTION (provided by applicant): Protein-based therapeutics currently represent one in every four new drugs approved by the FDA and command a market in excess of 30 billion. The vast majority of ...

    SBIR Phase I 2009 Department of Health and Human Services
  4. Glycophage arrays for the discovery of biomarkers in disease

    Amount: $200,000.00

    DESCRIPTION (provided by applicant): Many biological processes throughout the lifespan of a living organism are governed by discrete sugar structures and their interaction with protein and lipid molec ...

    SBIR Phase I 2009 Department of Health and Human Services
  5. Glycosylation of full-length antibodies in Escherichia coli

    Amount: $82,203.00

    DESCRIPTION (provided by applicant): Currently, therapeutic antibodies represent approximately 30% of all biotech revenues (gt 35 billion) and nearly all are produced in mammalian cell culture. Since ...

    SBIR Phase I 2009 Department of Health and Human Services
  6. Production of recombinant human glucocerebrosidase in Escherichia coli

    Amount: $175,860.00

    DESCRIPTION (provided by applicant): Gaucher's disease is the most common lysosomal storage disease in humans resulting in the harmful accumulation of fatty glucocerebroside in the spleen, liver, ...

    SBIR Phase I 2011 Department of Health and Human Services
  7. Engineering Escherichia coli for glycosylation of complex human proteins

    Amount: $1,608,039.00

    DESCRIPTION (provided by applicant): Escherichia coli was the host organism for production of the first approved recombinant protein therapeutic in 1982. We now know that most therapeutic proteins req ...

    SBIR Phase II 2011 Department of Health and Human Services
  8. Multiplexed Protein and miRNA Biomarker-based Next-gen Test for Alzheimers Disease

    Amount: $197,758.00

    DESCRIPTION: Therapeutic peptides are used to treat human diseases ranging from HIV to diabetes and have some of the best features of small molecule and recombinant protein drugs. Therapeutic peptide ...

    SBIR Phase I 2013 Department of Health and Human Services
  9. BOTTOM-UP GLYCOENGINEERING LIBRARY OF N-GLYCANS

    Amount: $299,450.00

    Glycans are directly involved in the pathology of many major diseases. Glycosylated biomolecules are involved in biological functions including cell signaling, cell growth, immunity, three-dimensiona ...

    SBIR Phase I 2013 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government